NCT05407441 2026-04-13
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
6 trialsNCT05551936 2026-02-17
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting
NCT07209163 2025-10-06
Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma
Ruijin Hospital
Phase 1/2 Not yet recruiting
NCT02889523 2024-10-09
Epi-RCHOP
The Lymphoma Academic Research Organisation
Phase 1/2 Active not recruiting
NCT05604417 2023-07-07
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Massachusetts General Hospital
Phase 1/2 Withdrawn
NCT05152459 2023-05-31
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
City of Hope Medical Center
Phase 1/2 Withdrawn